Abstract
Congestive heart failure is a major public health problem in most Western countries. In the United States, approximately 3 million people suffer from heart failure, 10% of whom are admitted to hospital each year [1]. Although in recent decades considerable advances in medical therapy have been achieved, especially by angiotensin-converting enzyme (ACE) inhibitors [2, 3], the mortality rate of heart failure still remains very high. In patients of New York Heart Association (NYHA) functional class II, there is a mortality rate of about 10% per year [4]. In order to improve this poor prognosis, additional pharmacological interventions to counteract the pathophysiological changes occurring in heart failure are still important.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Smith WM (1985) Epidemiology of congestive heart failure. Am J Cardiol 55: 3 – 8
The CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429 – 1435
The SOLVD Investigators (1991) Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293 – 302
Australia-New Zealand Heart Failure Research Collaborative Group (1995) Effects of Carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Circulation 92: 212 – 218
Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I (1975) Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 37: 1022 – 1036
Swedberg K, Hjalmarson A, Waagstein F, Wallentin I (1979) Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1: 1374 – 1376
Swedberg K, Hjalmarson A, Waagstein F, Wallentin I (1980) Adverse effects of beta-blocker withdrawal in patients with congestive cardiomyopathy. Br Heart J 44: 134 – 142
Swedberg K, Hjalmarson A, Waagstein F, Wallentin I (1980) Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 44: 117 – 133
Cohn JN, Levine TB, Olivari MT, Gerberg V, Lura D, Francis GS, Simon AB, Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819 – 823
Hausdorff WP, Caron MG, Lefkowitz RJ (1990) Turning off the signal: desensitization of β-adrenergic receptor function. FASEB J 4: 2881 – 2889
Bristow MR, Ginsburg R, Minobe W, et al (1982) Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med 307: 205 – 211
Böhm M, Gierschik P, Jakobs KH, Pieske B, Schnabel P, Ungerer M, Erdmann E (1990) Increase of Gia in human hearts with dilated but not ischemic cardiomyopathy. Circulation 82: 1249 – 1265
Ungerer M, Böhm M, Elce JS, Erdmann E, Lohse MJ (1993) Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation 87: 454 – 463
Gage J, Rutman H, Lucido D, Le Jemtel TH (1986) Additive effects of Dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 74: 367 – 373
Schwartz A, Lindenmayer GE, Harigaya S (1968) Respiratory control and calcium transport in heart mitochondria from the cardiomyopathic hamster. Trans N Y Acad Sci 30 (Suppl 2): 951
Feldman MD, Alderman JD, Aroesty JM, et al (1988) Depression of systolic and diastolic myocardial reserve during atrial pacing tachycardia in patients with dilated cardiomyopathy. J Clin Invest 82: 1661 – 1669
Schwinger RHG, Böhm M, Müller-Ehmsen J, et al (1993) Effect of inotropic stimulation on the negative force-frequency-relationship in the failing human heart. Circulation 88: 2267 – 2276
Eichhorn EJ, Bedotto JB, Malloy CR, et al (1990) Effects of ß-adrenergic receptor blockade on myocardial function and energetics in congestive heart failure. Circulation 82: 473 – 483
Andersson B, Hamm C, Persson S, et al (1994) Improved exercise hemodynamic status in dilated cardiomyopathy after beta-blockade treatment. J Am Coll Cardiol 23: 1397 – 1404
Ferro G, Duilio C, Spinelli L, et al (1991) Effects of beta-blockade on the relation between heart rate and ventricular diastolic perfusion time during exercise in systemic hypertension. Am J Cardiol 68: 1101 – 1103
Nicholas G, Oakley C, Pouleur H, et al (1990) Xamoterol in severe heart failure. Lancet 336: 1 – 6
Gilbert EM, Anderson JL, Deitchman D, et al (1990) Long-term betablocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med 88: 223 – 229
Gilbert EM, Abraham WT, Olsen S, et al (1996) Comparative hemodynamic, left ventricular functional and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 94: 2817 – 2825
Imperato-McGinley J, Gautier T, Ehlers K, et al (1987) Reversibility of catecholamine-induced dilated cardiomyopathy in a child with pheochromocytoma. N Engl J Med 316: 793 – 797
Cruickshank JM, Neil-Dwyer G, Degaute JP, et al (1987) Reduction of stress/catecholamine-induced cardiac necrosis by betal-selective blockade. Lancet 1: 585 – 589
Gilbert EM, Olsen SL, Renlund DG, Bristow MR (1993) Beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol 71: 23C – 29C
Sigmund M, Jakob H, Becker H (1996) Effects of metoprolol on myocardial β-adrenoceptors and Gia-proteins in patients with congestive heart failure. Eur J Clin Pharmacol 51: 127 – 132
Yoshikawa T, Port JD, Asaro K, et al (1996) Cardiac adrenergic receptor effects of carvedilol. Eur Heart J 17 (Suppl. B): 8 – 16
Whyte K, Jones CR, Howie CA, et al (1987) Haemodynamic metabolic and lymphocyte beta2-adrenoceptor changes following chronic beta-adrenoceptor antagonism. Eur J Clin Pharmacol 32: 237 – 243
Hall SA, Cigarroa CG, Marcoux L, et al (1995) Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 25: 1154 – 6131
Kukin ML, Kalman J, Mannino M, et al (1996) Combined alpha-betablockade (doxazosin and metoprolol) compared with beta-blockade alone in chronic congestive heart failure. Am J Cardiol 77: 486 – 491
Yue TL, Cheng H-J, Lysko PG, et al (1992) Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, is an antioxidant and free radical scavenger. J Pharmacol Exp Ther 263: 92 – 98
Yue T-L, Liu T, Feuerstein G (1992) Carvedilol, a new vasodilator and beta-adrenoceptor antagonist, inhibits oxygen radical mediated lipid per-oxidation in swine ventricular membranes. Pharmacol Communications 1: 27 – 35
Bolli R (1990) Mechanisms of myocardial stunning. Circulation 82: 723–738
Belch JJF, Bridges AB, Scott N, Chopra M (1991) Oxygen free radicals in congestive heart failure. Br Heart J 65: 245 – 248
Sung C-P, Arleth AJ, Ohlstein EH (1993) Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 21: 221 – 227
Ohlstein EH, Douglas SA, Sung C-P, et al (1993) Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration and neointimal formation following vascular injury. Proc Natl Acad Sci U S A 90: 6189 – 6193
Cleland JGF, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F (1996) Beta-blocking agents in heart failure - should they be used and how? Eur Heart J 17: 1629 – 1639
Waagstein F, Bristow MR, Swedberg K, et al (1993) Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342: 1441 – 1446
Fisher ML, Gottlieb SS, Plotnick G, et al (1994) Beneficial effects of metoprolol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 23: 943 – 950
CIBIS Investigators and Committees (1994) A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 90: 1765 – 1773
Woodley SL, Gilbert EM, Anderson JL, et al (1991) β-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 84: 2426 – 2441
Bristow MR, O’Connel JB, Gilbert EM, et al (1994) Dose-response of chronic β-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 89: 1632 – 1642
Packer M, Bristow MR, Cohn JN, et al. for the US carvedilol study group (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 334: 1349 – 1355
Australia-New Zealand Heart Failure Research Collaborative Group (1997) Randomized, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 349: 375 – 380
Waagstein F, Caidahl K, Wallentin I, et al (1989) Long-term beta-blockade in dilated cardiomyopathy: effects of short-and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 80: 551 – 563
Lahiri A, Rodrigues EA, Al-Khawaja I, et al (1987) Effect of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina-pectoris. Am J Cardiol 59: 769 – 774
Awan NA, Needham KE, Evenson MK, et al (1981) Therapeutic application of prazosin in chronic refractory congestive heart failure: tolerance and “tachyphylaxis” in perspective. Am J Med 71: 153 – 160
Metra M, Nardi M, Giubbini R (1994) Effects of short-and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 24: 1678 – 1687
Doughty RN, Whalley GA, Gamble G, et al. on behalf of the Australia-New Zealand Heart Failure Research Collaborative Group (1997) Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 29: 1060 – 1066
Gaudron P, Eilles C, Kugler I, Ertl G (1993) Progressive left ventricular dysfunction and remodeling after myocardial infarction. Potential mechanisms and early predictors. Circulation 87: 755–763
Hammermeister KE, De Rouen TA, Dodge HAT (1979) Variables predictive of survival in patients with coronary disease: selection by univariate and multivariate analyses from the clinical, electrocardiographic, exercise, arteriographic and quantitative angiographic evaluations. Circulation 59: 421 – 430
White HD, Norris RM, Brown MA, Brandt PWT, Whitlock RML, Wild CJ (1987) Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 76: 44 – 51
Sharpe N, Murphy J, Smith H, Hannan S (1988) Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet: 255 – 259
Sutton MSJ, Pfeffer MA, Plappert T, et al (1994) Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. Circulation 89: 68 – 75
Cohn JN (1994) Vasodilators in heart failure: conclusions from V-HeFT II and rationale for V-HeFT III. Drugs 47 (Suppl 4): 47 – 58
Hash TW, Prisant LM (1997) ß-blocker use in systolic heart failure and dilated cardiomyopathy. J Am Coll Cardiol 37: 7 – 19
Swedberg K (1994) Exercise testing in heart failure: a critical review. Drugs 47 (Suppl 4): 14 – 24
Heilbrunn SM, Shah P, Bristow MR, et al (1989) Increased ß-receptor density and improved hemodynamic response to catecholamine stimulation during long-term metoprolol therapy in heart failure from dilated cardiomyopathy. Circulation 79: 483 – 490
Böhm M, Deutsch HJ, Hartmann D, La Rosée K, Stäblein A (1997) Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol 30: 992 – 996
White M, Yanowitz F, Gilbert EM, et al (1995) Role of β-adrenergic receptor downregulation in the peak exercise response in patients with heart failure due to idiopathic dilative cardiomyopathy. Am J Cardiol 76: 1271 – 1276
Packer M, Arver JR, Rodeheffer RJ, et al. for the PROMISE Study Research Group (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325: 1468 – 1475
The Digitalis Investigation Group (DIG) (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 336: 525 – 533
Lipicky RJ, Packer M (1993) Role of surrogate end points in the evaluation of drugs for heart failure. J Am Coll Cardiol 22 (Suppl A): 179A–184A
Colucci WS, Packer M, Bristow MR, et al (1996) Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 94: 2800 – 2806
Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N (1996) Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators [comment]. Circulation 94: 2807–2816
Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS et al. for the PRECISE Study Group (1996) Double-blind, placebo controlled study of the effects of carvedilol in patients with moderate to severe heart failure: the PRECISE trial. Circulation 94: 2793 – 2799
Cohn J, Fowler MB, Bristow MR, et al (1997) Safety and efficacy of carvedilol in severe chronic heart failure. J Card Failure 3: 173 – 179
Pfeffer MA, Stevenson LW (1996) β-adrenergic blockers and survival in heart failure. N Engl J Med 334: 1396 – 1397
Parmershwar J, Shackel MM, Richardson A, Poole-Wilson PA, Sutton GC (1992) Prevalence of heart failure in three general practices in northwest London. Br J Gen Pract 42: 287 – 289
Sutton GC (1990) Epidemiologic aspects of heart failure. Am Heart J 120: 1538 – 1540
Marwood JF, Stokes GS (1986) Studies on the vasodilator actions of bucindolol in the rat. Clin Exp Pharmacol Physiol 13: 59 – 68
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1998 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Maack, C., Böhm, M. (1998). β-Blocker Treatment of Chronic Heart Failure. In: Böhm, M., Laragh, J.H., Zehender, M. (eds) From Hypertension to Heart Failure. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60300-6_10
Download citation
DOI: https://doi.org/10.1007/978-3-642-60300-6_10
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-63542-0
Online ISBN: 978-3-642-60300-6
eBook Packages: Springer Book Archive